About
Rheumatoid Arthritis (RA) is a chronic systemic disease in which immunologically mediated inflammation of synovia-lined joints can result in marked disruption of joint structure and function.The most common form of this disease is chronic inflammatory arthritis, which begins with inflammation of the synovial membrane of the affected joints and eventually leads to disability of the affected limb. Over time, it typically leads to the destruction of cartilage and bone, joint deformity, and organ failure, and eventually results in disability.
The number of affected joints and other organs usually increases with rapid disease progression. The treatment and the diagnostics of RA have been evolved through the years; the first non-specific medication was aspirin, followed by more appropriate drugs, such as cortisone, and methotrexate, and the revolution arrived within the last 20 years with biologics. Simultaneously diagnostics have been improved, starting from the detection of Rheumatoid Factor (RF) only to progressing to completing the diagnosis by the new ACPA (anti-citrullinated protein antibodies) tests, like citrulline peptide (anti-CCP) and citrullinated vimentin (MCV).
These improvements in the diagnostic tools are included in the ACR-EULAR classification criteria for RA, established in 2010 as a pillar for the correct management of patients affected by RA.
Diagnosis
Autoantibodies against citrullinated peptides/proteins (ACPA), e.g. anti-MCV, anti-CCP, and RF are essential components of the ACR/EULAR criteria for classification of RA.
Anti-MCV
- Measurement of autoantibodies against mutated citrullinated vimentin as a useful additional marker, particularly in patients who are anti-CCP negative
- Highly specific and extremely sensitive for RA
Anti-CCP hs
- Tailored antigen profile for enhanced autoantibody recognition
- Numerous different epitopes for higher sensitivity
Rheumatoid Factor IgM, IgA, IgG
- Quantitative measurement of individual RF isotypes
- IgM + IgA RF double positive is highly specific for RA
Sebia’s Expertise
Sebia offers the largest portfolio for RA laboratory diagnostics with the Alegria Monotest random access solution, and ELISA testing for high throughput. A special proprietary antigen coating procedure ensures reliable test results, excellent accuracy, reproducibility, and consistency, minimizing the risk of misdiagnosis and inappropriate treatment. Sebia´s superior ELISA-based immunoassays comply with the latest ACR/EULAR RA 2010 classification criteria. The all-in-one Alegria Monotest is particularly suited for small series and offers unique flexibility for maximum workflow efficiency with the Alegria 2 system.
Featured resources on Rheumatoid Arthritis diagnosis
See all resourcesUnlocking the power of anti-MCV detection for early diagnosis of Rheumatoid Arthritis
Educational Webinar with Holger Bang, PhD & Roberto Fiorillo
Anti-MCV – Fill the gap in rheumatoid arthritis diagnosis
This comprehensive meta-analysis highlights the benefit of testing anti-MCV additionally to anti-CCP and RF in the context of early diagnosis of Rheumatoid Arthritis.
Alegria 2 properties and workflow
Obtain your patients results with high flexibility reliability and efficiency with Alegria 2.
Customer Testimonial about the Alegria 2
The Alegria 2 provides the possibility of giving results to clinicians within a timeframe fitting clinical needs and helps to optimize the patient’s care pathway.
Upcoming events
See all events
Rheumatoid Arthritis
A holistic portfolio with Anti-MCV to unlock the full potential of early diagnosis.
Learn more about our unique technologies
- Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9. doi: 10.1093/rheumatology/kes279. PMID: 23221588.
- Zhu JN, Nie LY, Lu XY, Wu HX. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? Clin Chem Lab Med. 2019 Oct 25;57(11):1668-1679. doi: 10.1515/cclm-2019-0167. PMID: 31141478.
- Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007 Aug;56(8):2503-11. doi: 10.1002/art.22817. PMID: 17665451.
- Bertin D, Dubucquoi S, Lakomy D, Deleplancque AS, Desplat-Jégo S. Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis. Immunol Res. 2016 Apr;64(2):455-60. doi: 10.1007/s12026-015-8690-9. PMID: 26350265.
- Kuna AT. Mutated citrullinated vimentin antibodies in rheumatoid arthritis. Clin Chim Acta. 2012 Jan 18;413(1-2):66-73. doi: 10.1016/j.cca.2011.10.020. Epub 2011 Oct 19. PMID: 22037509.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.